Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - atenolol, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; pregelatinised maize starch; hypromellose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; indigo carmine; methylcellulose; macrogol 400 - atenolol is indicated in the management of: 1. all grades of hypertension, including hypertension of renal origin. 2. frequent disabling angina without evidence of cardiac failure. 3. cardiac arrhythmias (maintenance treatment of supraventricular and ventricular arrhythmiaswhich have been controlled with intravenous atenol, including those associated with acute myocardial infarction). 4. myocardial infarction: late intervention (beta-blocker class effect).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - atenolol, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; hypromellose; sodium starch glycollate; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; titanium dioxide; indigo carmine; methylcellulose; macrogol 400 - atenolol is indicated in the management of: 1. all grades of hypertension, including hypertension of renal origin. 2. frequent disabling angina without evidence of cardiac failure. 3. cardiac arrhythmias (maintenance treatment of supraventricular and ventricular arrhythmias, including those associated with acute myocardial infarction). 4. myocardial infarction: late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - calcitriol -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - codeine phosphate hemihydrate,paracetamol -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - captopril, quantity: 50 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; stearic acid; maize starch; lactose monohydrate - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recom

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - captopril, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; stearic acid; microcrystalline cellulose; maize starch - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recom

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 25 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see  error! hyperlink reference not valid. and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see  warnings  and  dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated du

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - diclofenac sodium -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - diclofenac sodium -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; purified talc; disodium edetate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - amitriptyline alphapharm 50mg tablets are indicated only for the maintenance treatment of major depression. (see precautions). nocturnal enuresis where organic pathology has been excluded.